Endothelin-1 induces tumor proteinase activation and invasiveness of ovarian carcinoma cells

Cancer Research

Volumn 61, Issue 22, 2001, Pages 8340-8346

  Rosano L ^a   Varmi, M ^a   Salani, D ^a   Di Castro, V ^a   Spinella, F ^a   Natali, P G ^a   Bagnato, A ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; ENDOTHELIN 1; MATRIX METALLOPROTEINASE; MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; UROKINASE;

ARTICLE; CANCER CELL; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; OVARY CARCINOMA; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

CELL MOVEMENT; ENDOTHELIN-1; ENZYME ACTIVATION; FEMALE; HUMANS; MATRIX METALLOPROTEINASES; NEOPLASM INVASIVENESS; OVARIAN NEOPLASMS; PLASMINOGEN INACTIVATORS; RECEPTORS, CELL SURFACE; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TUMOR CELLS, CULTURED; URINARY PLASMINOGEN ACTIVATOR;

EID: 0035890357     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Carcinoma of the ovary: A clinicopathological study of 86 autopsied cases with a special reference to mode of spread
2. Endothelins
3. Autocrine actions of endothelin-1 as a growth factor in human ovarian carcinoma cells
4. Expression of endothelin-1 and endothelin A receptor in ovarian carcinoma: Evidence for an autocrine role in tumor growth
5. Transactivation of epidermal growth factor receptor in endothelin-1 induced mitogenic signaling in human ovarian carcinoma cells
6. Activation of mitogenic signaling by endothelin-1 in ovarian carcinoma cells
7. Endothelin-1 induces an angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo
8. Role of endothelin-1 in neovascularization of ovarian carcinoma
9. Emerging roles for proteinases in cancer
10. Cancer invasion and tissue remodeling: Common themes in proteolytic matrix degradation
11. Matrix metalloproteinases: Multifunctional contributors to tumor progression
12. Expression and activity of MMPs and their regulators in ovarian cancers
13. In vitro degradation of extracellular matrix by human ovarian carcinoma cells
14. The role of proteolytic enzyme in the pathology of epithelial ovarian carcinoma
15. Matrix metalloproteinase-2 and tissue inhibitor of metallaproteinase-2 expression and synthetic matrix metalloproteinase-2 inhibitor binding in ovarian carcinomas and tumor cell lines
16. The matrix metalloproteinase stromelysin-1 acts as a natural mammary tumor promoter
17. Matrilysin: An epithelial matrix metalloproteinase with potentially novel functions
18. An overview of collagenase-3 expression in malignant tumors and analysis of its potential value as a target in antitumor therapies
19. 1 integrin
20. Membrane-type metalloproteinase expression and matrix metalloproteinase-2 activation in primary human ovarian epithelial carcinoma cells
21. Tissue inhibitors of metalloproteinases: Structure, regulation and biological functions
22. The urokinase-type plasminogen activator system in cancer metastasis: A review
23. Urokinase plasminogen activator and malignancy
24. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients
25. The significance of urokinase-type plasminogen activator, its inhibitors, and its receptor in ascites of patients with epithelial ovarian cancer
26. The level of urokinase-type plasminogen activator is increased in serum of ovarian cancer patients
27. Semiquantitative analysis of cytokine gene expression in blood and cerebrospinal fluid cells by reverse transcriptase polymerase chain reaction
28. A rapid in vitro assay for quantitating the invasive potential of tumor cells
29. Coordinate expression of urinary-type plasminogen activator and its receptor accompanies malignant transformation of the ovarian surface epithelium
30. Cell migration: A physically integrated molecular process
31. Secretion of extracellular matrix-degrading proteinases is increased in epithelial ovarian carcinoma
32. Lysophosphatidic acid induces urokinase secretion by ovarian cancer cells
33. Lysophosphatidic acid promotes matrix metalloproteinase (MMP) activation and MMP-dependent invasion in ovarian cancer cells
34. The association of transforming growth factor-β1 with myometrial invasion of endometrial carcinomas through effects of matrix metalloproteinase
35. Effects of EGF and TGF-α on invasion and proteinase expression of uterine cervical adenocarcinoma OMC-4 cells
36. Remodeling of collagen matrix by human tumor cells requires activation and cell surface association of matrix-metalloproteinase-2
37. Matrix metalloproteinases and metastasis
38. Induction of matrix metalloproteinase activation cascades based on membrane-type l matrix metalloproteinase: Associated activation of gelatinase A, gelatinase B and collagenase 3
39. MT1-MMP and MMP mRNA expression in human ovarian tumors: Possible implications for the role of desmoplastic fibroblasts
40. TIMP-2 over-expression reduces invasion and angiogenesis and protects B 16F10 melanoma cells from apoptosis
41. Tumor targeting with a selective gelatinase inhibitor
42. The plasminogen activation system in tumor growth, invasion and metastasis
43. Cell membrane receptors for urokinase plasminogen activator are increased in malignant ovarian tumors
44. Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator, its receptor, and inhibitors types 1 and 2
45. Absence of host plasminogen activator inhibitor-l prevents cancer invasion and vascularization
46. Remarkable roles of proteolysis on and beyond the cell surface
47. Proteases as prognostic markers in cancer
48. Cancer biology: Extracellular proteinases in malignancy